PTGX

Protagonist Therapeutics (PTGX)

About Protagonist Therapeutics (PTGX)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Details

Daily high

$37.43

Daily low

$36.34

Price at open

$36.98

52 Week High

$48.89

52 Week Low

$24.21

Market cap

2.2B

Dividend yield

0.00%

Volume

485,307

Avg. volume

556,255

P/E ratio

13.81

Protagonist Therapeutics News